<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/21/recent-investment-analysts-ratings-updates-for-intelgenx-technologies-igxt.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-21T07:08:46+00:00"/>
    <meta property="og:title" content="Recent Investment Analysts’ Ratings Updates for IntelGenx Technologies (IGXT)"/>
    <meta property="og:description" content="A number of research firms have changed their ratings and price targets for IntelGenx Technologies (OTCMKTS: IGXT): 11/20/2019 – IntelGenx Technologies was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “IntelGenx is a drug delivery company focused on the development of oral controlled-release products as […]"/>
  </head>
  <body>
    <article>
      <h1>Recent Investment Analysts’ Ratings Updates for IntelGenx Technologies (IGXT)</h1>
      <address><time datetime="2019-11-21T07:08:46+00:00">21 Nov 2019, 07:08</time> by <a rel="author" href="https://www.thecerbatgem.com/author/renee" target="_blank">Renee Jackson</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/intelgenx-technologies-corp-logo.png"/>
      </figure>
      <p>A number of research firms have changed their ratings and price targets for <b>IntelGenx Technologies</b> (OTCMKTS: IGXT):</p>
      <ul>
        <li>11/20/2019 – IntelGenx Technologies was upgraded by analysts at <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> from a “sell” rating to a “hold” rating. According to Zacks, “IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The Company’s research and development pipeline includes products for the treatment of osteoarthritis pain management, hypertension and smoking cessation. “</li>
        <li>11/14/2019 – IntelGenx Technologies was downgraded by analysts at <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> from a “hold” rating to a “sell” rating. According to Zacks, “IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The Company’s research and development pipeline includes products for the treatment of osteoarthritis pain management, hypertension and smoking cessation. “</li>
        <li>11/12/2019 – IntelGenx Technologies had its “buy” rating reaffirmed by analysts at Echelon Wealth Partners. They now have a $1.60 price target on the stock.</li>
        <li>11/11/2019 – IntelGenx Technologies had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $1.00 price target on the stock.</li>
        <li>11/6/2019 – IntelGenx Technologies was upgraded by analysts at <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=IGXT">ValuEngine</a> from a “hold” rating to a “buy” rating.</li>
        <li>10/28/2019 – IntelGenx Technologies had its “speculative buy” rating reaffirmed by analysts at Echelon Wealth Partners.</li>
        <li>10/25/2019 – IntelGenx Technologies was downgraded by analysts at <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=IGXT">ValuEngine</a> from a “buy” rating to a “hold” rating.</li>
        <li>10/15/2019 – IntelGenx Technologies was upgraded by analysts at <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> from a “sell” rating to a “hold” rating. According to Zacks, “IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The Company’s research and development pipeline includes products for the treatment of osteoarthritis pain management, hypertension and smoking cessation. “</li>
        <li>9/30/2019 – IntelGenx Technologies was upgraded by analysts at <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=IGXT">ValuEngine</a> from a “hold” rating to a “buy” rating.</li>
      </ul>
      <p><a href="https://www.marketbeat.com/stocks/OTCMKTS/IGXT/price-target/">IntelGenx Technologies stock</a> opened at $0.52 on Thursday. IntelGenx Technologies Corp. has a 12 month low of $0.39 and a 12 month high of $0.80. The firm has a market cap of $51.10 million, a PE ratio of -3.71 and a beta of 1.84. The company has a current ratio of 2.07, a quick ratio of 1.92 and a debt-to-equity ratio of 2.76. The stock’s 50 day simple moving average is $0.62 and its two-hundred day simple moving average is $0.52.</p>
      <p>IntelGenx Technologies (OTCMKTS:IGXT) last announced its earnings results on Thursday, November 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.03). IntelGenx Technologies had a negative return on equity of 162.47% and a negative net margin of 792.90%. The firm had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.20 million. On average, equities research analysts forecast that IntelGenx Technologies Corp. will post -0.11 EPS for the current year.</p>
      <p>IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease.</p>
      <p>See Also: <a href="https://www.marketbeat.com/financial-terms/What-is-a-dividend-reinvestment-plan/">What is a dividend reinvestment plan?</a></p>
    </article>
  </body>
</html>